Entrada Therapeutics Ownership | Who Owns Entrada Therapeutics?
Entrada Therapeutics Ownership Summary
Entrada Therapeutics is owned by 69.99% institutional investors, 12.27% insiders, and 17.74% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 12.13% of TRDA shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.01% of its assets in Entrada Therapeutics shares.
TRDA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Entrada Therapeutics | 69.99% | 12.27% | 17.74% |
| Sector | Healthcare Stocks | 244.59% | 12.11% | -156.70% |
| Industry | Biotech Stocks | 379.61% | 11.70% | -291.31% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Baker bros. advisors lp | 5.07M | 12.13% | $37.34M |
| Mpm asset management | 4.38M | 10.60% | $25.41M |
| 5am venture management | 4.06M | 9.70% | $29.85M |
| Blackrock funding, inc. /de | 2.58M | 6.17% | $19.01M |
| Janus henderson group | 2.08M | 5.12% | $36.01M |
| Blackrock | 1.69M | 5.06% | $24.14M |
| Merck | 1.74M | 4.16% | $12.80M |
| Vanguard group | 1.63M | 3.94% | $16.78M |
| Vanguard capital management | 1.27M | 3.03% | $9.34M |
| Bioimpact capital | 1.25M | 3.00% | $9.22M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mpm asset management | 4.38M | 57.09% | $25.41M |
| 5am venture management | 4.06M | 10.37% | $29.85M |
| Merck | 1.74M | 2.43% | $12.80M |
| Bioimpact capital | 1.25M | 0.56% | $9.22M |
| Corton capital | 38.85K | 0.55% | $225.32K |
| Nan fung group | 49.08K | 0.27% | $361.24K |
| Stepstone group lp | 761.28K | 0.26% | $5.60M |
| Lynx1 capital management lp | 178.61K | 0.26% | $1.31M |
| Verdad advisers, lp | 27.50K | 0.19% | $202.40K |
| Tcg crossover management | 1.06M | 0.19% | $7.80M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Merck | 1.74M | 2.43% | 1.74M |
| Bioimpact capital | 1.25M | 0.56% | 1.25M |
| Aqr capital management | 699.54K | 0.00% | 620.04K |
| Jpmorgan chase | 496.46K | 0.00% | 481.61K |
| Janus henderson group | 2.08M | 0.02% | 368.91K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tcg crossover management | 1.06M | 0.19% | -1.23M |
| Redmile group | - | - | -560.97K |
| Algert global | - | - | -128.61K |
| Nuveen | 56.78K | 0.00% | -118.87K |
| Sphera funds management | - | - | -110.94K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Merck | 1.74M | 2.43% | 1.74M | $12.80M |
| Bioimpact capital | 1.25M | 0.56% | 1.25M | $9.22M |
| Sixth street partners management company | 197.14K | 0.00% | 197.14K | $1.45M |
| Cubist systematic strategies | 122.68K | 0.00% | 122.68K | $711.52K |
| Gsa capital partners llp | 88.00K | 0.04% | 88.00K | $648.00K |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -4.00 |
| Amundi | -12.00 |
| Parallel advisors | -16.00 |
| Quadrant capital group | -18.00 |
| Advantage alpha capital partners lp | -20.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 129 | 8.40% | 29,281,617 | 14.93% | 69 | 1.85% | 83 | 22.06% | 30 | - |
| Mar 31, 2026 | 43 | -62.28% | 3,082,918 | -87.38% | 7 | 0.21% | 27 | -46.00% | 6 | -85.71% |
| Dec 31, 2025 | 62 | -47.01% | 7,762,092 | -72.74% | 18 | 0.39% | 24 | -68.00% | 24 | -11.11% |
| Sep 30, 2025 | 62 | -38.00% | 8,507,595 | -70.84% | 20 | 0.41% | 35 | -44.44% | 20 | -4.76% |
| Jun 30, 2025 | 105 | -4.55% | 29,576,026 | 37.87% | 71 | 2.62% | 66 | 37.50% | 23 | -45.24% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| US Small-Cap Growth II Equity Comp | 1.52M | 4.01% | -163.10K |
| T. Rowe Price New Horizons | 1.37M | 3.59% | -157.39K |
| Vanguard Total Stock Mkt Idx Inv | 953.73K | 2.46% | - |
| Vanguard Morn Total Stk Mkt Idx Investor | 953.73K | 2.46% | - |
| Vanguard MStar Total Stk Mkt Idx Invest | 953.73K | 2.45% | - |
| iShares Russell 2000 ETF | 751.35K | 1.93% | -13.34K |
| Fidelity Growth Compy Commingled Pl O | 561.18K | 1.51% | - |
| T. Rowe Price New Horizons Tr-A | 459.17K | 1.21% | 7.79K |
| T. Rowe Price New Horizons Tr-Z | 451.38K | 1.20% | 649.00 |
| MEDICAL BioHealth EUR Acc | 454.20K | 1.17% | -220.00 |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 09, 2026 | MPM BIOVENTURES 2018, L.P. | - | Sell | $205.61K |
| Sep 04, 2026 | MPM BIOVENTURES 2018, L.P. | - | Sell | $273.74K |
| Sep 08, 2026 | MPM BIOVENTURES 2018, L.P. | - | Sell | $1.43M |
| Sep 04, 2026 | MPM BioVentures 2014, L.P. | - | Sell | $273.74K |
| Sep 08, 2026 | MPM BioVentures 2014, L.P. | - | Sell | $1.43M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 33 |
| 2026 Q2 | 1 | 3 |
| 2026 Q1 | - | 5 |
| 2025 Q4 | 16 | 3 |
| 2025 Q3 | - | 8 |
TRDA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools